Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Alabama: - Clinical Study Site — Mobile, Alabama
- Clinical Study Site — Tuscaloosa, Alabama
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Alabama: - Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621 — Huntsville, Alabama
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Alabama: - UAB Medicine - UAB Hospital — Birmingham, Alabama
Phase 2 Recruiting Industry
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line …
Sponsor: Oncolytics Biotech
NCT ID: NCT07446322
Sites in Alabama: - Central Alabama Research — Homewood, Alabama
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Academic/Other
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or me…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT05868226
Sites in Alabama: - The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, lo…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Alabama: - Dothan Hematology & Oncology — Dothan, Alabama
Phase 1 Recruiting Industry
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Alabama: - UAB Comprehensive Cancer Center — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally adva…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Alabama: - Uni of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
NA Recruiting Academic/Other
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal pol…
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05612347
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Alabama: - Research Site — Birmingham, Alabama
NA Recruiting Industry
The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged 45-84 that are of average risk to develop colorectal cancer and have received a…
Sponsor: Jubaan Ltd.
NCT ID: NCT07623902
Sites in Alabama: - East View Medical Research, LLC — Mobile, Alabama
NA Recruiting Academic/Other
The purpose of this study is to test whether the timing of meals can improve treatment adverse events, influence tumor biology and alter a person's mood and behaviors.
Sponsor: Cedars-Sinai Medical Center
NCT ID: NCT04722341
Sites in Alabama: - The University of Alabama at Birmingham — Birmingham, Alabama